Player FM - Internet Radio Done Right
Checked 14h ago
تمت الإضافة منذ قبل two أعوام
المحتوى المقدم من Pharma and BioTech News and BioTech News. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Pharma and BioTech News and BioTech News أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
Player FM - تطبيق بودكاست
انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !
انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !
المدونة الصوتية تستحق الاستماع
برعاية
<
<div class="span index">1</div> <span><a class="" data-remote="true" data-type="html" href="/series/before-the-chorus">Before The Chorus</a></span>


Before a song is released, a record is produced, or a chorus is written, the musicians that write them think. A lot. They live. A lot. And they feel. A LOT. Hosted by award-winning interviewer and radio host Sofia Loporcaro, Before the Chorus dives into the stories and experiences that shape these artists, and ultimately, the music we hear.
Pharma and BioTech Daily
وسم كل الحلقات كغير/(كـ)مشغلة
Manage series 3478766
المحتوى المقدم من Pharma and BioTech News and BioTech News. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Pharma and BioTech News and BioTech News أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
This podcast aims to bring you a daily summary of the most relevant news in Pharma and BioTech. Check our website at: https://www.buzzsprout.com/2189790
72 حلقات
وسم كل الحلقات كغير/(كـ)مشغلة
Manage series 3478766
المحتوى المقدم من Pharma and BioTech News and BioTech News. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Pharma and BioTech News and BioTech News أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
This podcast aims to bring you a daily summary of the most relevant news in Pharma and BioTech. Check our website at: https://www.buzzsprout.com/2189790
72 حلقات
كل الحلقات
×
1 Pharma and Biotech Daily: Insights from the Industry Leaders 1:25
1:25
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب1:25
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Johnson & Johnson reported second-quarter earnings of $23.7 billion, driven by cancer and neuroscience drugs, exceeding analyst expectations. CEO Joaquin Duato set a target of $50 billion in oncology sales by 2030. Despite challenges in the industry, Johnson & Johnson remains optimistic about its oncology sales target as the biotech industry continues to navigate the evolving landscape of drug development and funding.In a difficult investing environment where IPOs are not guaranteed, AI-focused biotech unicorns are facing challenges in securing funding. GSK's Blenrep is facing setbacks as the FDA questions its efficacy in treating multiple myeloma, while AstraZeneca's amyloidosis asset failed to improve survival in a late-stage trial. The industry is also seeing the rise of women leaders like Audrey Greenberg and the team at Acadia, who are making significant contributions to the field.Biospace is launching a new weekly newsletter focused on critical manufacturing issues in the biopharma industry, covering developments and impacts on companies such as Roche, Sanofi, and Johnson & Johnson. The newsletter aims to provide deep dives, analysis, and roundups of the biggest manufacturing stories of the week every Tuesday. Stay informed with weekly analysis and updates on the changing landscape of manufacturing in the U.S.…

1 Pharma and Biotech Daily: Your Morning Dose of Industry Updates 1:06
1:06
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب1:06
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The U.S. Department of Health and Human Services (HHS) has begun formally laying off thousands of employees following a Supreme Court ruling allowing the Trump administration to reorganize the agency. FDA Commissioner Marty Makary has proposed lowering industry user fees to make it easier for smaller companies and academics to participate in the regulatory process. Developments in HIV and prep treatments are being presented at the IAS 2025 conference, while a new dual glp-1/gip molecule from Hengrui and Kailera Therapeutics has shown promising weight loss results in Phase III trials. A new 96-channel pipettor from Rainin is also being promoted to streamline library preparation for next-generation sequencing. Updates on Acadia's pipeline, FDA rejections for Ultragenyx, advancements in narcolepsy treatments by Takeda, and the potential use of psychedelics in depression treatment are also discussed in this episode. Stay tuned for more updates on the latest news and developments in the pharmaceutical and healthcare industries.…

1 Pharma and Biotech Daily: Navigating the Latest in Drug Development and Innovation 2:11
2:11
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب2:11
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Takeda has taken the lead in the race for a narcolepsy treatment with back-to-back phase III wins for their drug Oveporexton. Investors are eagerly awaiting breakthroughs in using psychedelics to treat depression. Ultragenyx faced a setback as the FDA rejected their gene therapy for Sanfilippo syndrome, citing manufacturing issues. The FDA is considering speeding up reviews for companies that promise to lower drug costs. Market reaction to recent readouts from Compass Pathways and Beckley Psytech/Atai in treatment-resistant depression shows the challenges psychedelic therapies must overcome for commercial viability. Rainin Micropro offers a solution to streamline NGS preparation with their 96-channel pipettor. The industry is also focused on precision diagnostics to support precision therapeutics in the future. AstraZeneca's Baxdrostat showed promising results in lowering blood pressure in a phase III trial. The ADA revealed R&D priorities for potential blockbuster obesity treatments. Relmada has abandoned development of a depression drug after three failed attempts.The challenges faced by psychedelic therapies in the treatment of depression are discussed, as recent readouts from Compass Pathways and Beckley Psytech/Atai in treatment-resistant depression have left investors wanting more. The market reaction highlights the hurdles psychedelic therapies must overcome to prove their commercial viability. Additionally, the importance of precision diagnostics in the development of next-generation precision oncology therapies is emphasized, stating that only with the adoption of digital imaging and AI-powered analysis will these therapies reach their full potential. The FDA has several important decisions lined up, including applications in lymphoma, rare diseases, and hormone deficiency, while the American Diabetes Association's annual meeting reveals R&D priorities for weight loss medicines. Topics discussed include Capricor's FDA rejection of a DMD cell therapy, the ALS community petitioning the FDA to reconsider Brainstorm's Nurown, and updates on COVID-19 vaccines and Alzheimer's drugs. Upcoming webinars and job opportunities in the biopharma industry are also included.…

1 Pharma and Biotech Daily: FDA Rejections, Vaccine Approvals, and Industry Acquisitions 1:01
1:01
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب1:01
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The FDA has rejected Capricor's therapy for Duchenne Muscular Dystrophy (DMD), causing shares to plunge due to insufficient evidence of effectiveness for cardiomyopathy associated with DMD. Lilly and Sarepta also received Complete Response Letters (CRLs) for their therapies. Moderna has won full approval for its COVID-19 vaccine for higher-risk kids, while Pacira has cut staff in San Diego. The FDA has released a cache of CRLs, providing insights into the journeys to market for various drugs. AbbVie has acquired Ichnos Glenmark's lead myeloma antibody, and Ultragenyx's stock plummeted after a late-stage trial disappointment. Kennedy postponed a preventive care panel meeting after a Supreme Court win. Transitioning from one piece of news to the next, let's move on to the webinar exploring digitization strategies for drug development. Stay tuned for more updates in the pharmaceutical industry.…

1 Insights from Pharma and Biotech: CRL Transparency, Acquisition Updates, and Digitization Strategies 1:28
1:28
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب1:28
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.The FDA has recently released over 200 complete response letters (CRLs) as part of its initiative to enhance transparency regarding the reasons behind the rejection of new drug and biologics applications. This effort reflects the agency's commitment to being more open with the public about its decision-making processes.In other news, AbbVie has made a significant acquisition by purchasing Ichnos Glenmark's lead myeloma antibody for nearly $2 billion, including a substantial upfront payment of $700 million. However, Ultragenyx and Mereo Biopharma faced challenges as their stocks declined following the announcement that the phase II/III study of their osteogenesis imperfecta candidate did not yield strong results during an interim analysis.Furthermore, there is growing concern surrounding the potential dismissal of the U.S. Preventive Services Task Force, following a Supreme Court ruling that affirmed Health Secretary Robert F. Kennedy Jr.'s authority to remove its members at his discretion. This development has raised questions about the future of preventive health initiatives in the country.For drug developers, finding the right balance between speed and quality is essential for achieving success in the industry. To optimize processes and leverage technology throughout the development journey, new digitization strategies are being explored. Embracing these advancements can help streamline operations and enhance overall efficiency in drug development efforts.…

1 Pharma and Biotech Daily: Merck's Acquisition, Supreme Court Ruling, and Trump's Tariff Threats 1:04
1:04
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب1:04
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Merck recently made a significant move in the pharmaceutical industry by acquiring Verona for $10 billion, gaining access to the commercial COPD drug Ohtuvayre. This acquisition is viewed as a strategic decision to offset potential revenue loss when the patent for Keytruda expires. In other news, the Supreme Court has suspended an injunction preventing RFK Jr.'s HHS cuts. AstraZeneca also finalized a deal with JCR worth up to $825 million for gene therapy AAVs. Additionally, Trump has threatened 200% pharma tariffs, but has provided a one-year grace period for implementation. Drug developers are being advised to digitize their outsourcing path for optimal success in the industry. Furthermore, Novo Nordisk has terminated a deal with Hims & Hers, while Lilly has received an FDA label update for an Alzheimer's drug. Various developments in the longevity biotech space have also been highlighted. Stay tuned for more updates in the pharmaceutical industry.…

1 Pharma and Biotech Daily: Legal Battles, Acquisitions, Policy Changes, and Innovation 1:11
1:11
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب1:11
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Medical societies, including the American Academy of Pediatrics, have filed a lawsuit against RFK Jr. over changes to COVID-19 vaccine policies. They argue that his directive to remove COVID-19 from vaccination guidelines for healthy pregnant women and children puts them at risk of serious illness. Concentra has acquired struggling biotech company Cargo Therapeutics in a $200 million buyout. President Trump's tax law has restored orphan drug exemptions, cut Medicaid funding, and threatened the 340B program, while giving pharmacy benefit managers a pass. The ALS community has petitioned the FDA to reconsider Brainstorm's cell therapy Nurown, citing recent survival data. Drug developers are exploring new digitization strategies to optimize processes and embrace technology in drug development. Overall, the text discusses legal action against RFK Jr. over vaccine policy changes, recent acquisitions in the biotech industry, implications of Trump's tax law on healthcare programs, petitions regarding ALS therapies, digitization strategies in drug development.…

1 Pharma and Biotech Daily: Latest in Drug Approvals, Biopharma Milestones, and Industry Trends 1:17
1:17
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب1:17
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Kalvista has received approval for the first on-demand hereditary angioedema pill after facing challenges with the FDA. Meanwhile, Robert F. Kennedy Jr. has made significant cuts and rehires at the Department of Health and Human Services. Upcoming biopharma milestones to watch include developments in obesity and rare genetic diseases, as well as therapies targeting the TIGIT space. Drug developers are exploring digitization strategies to optimize processes and embrace technology in the development journey amidst a busy buyout period in the pharmaceutical industry.Transitioning to the next news, the text discusses four therapies targeting TIGIT that are still holding on in a troubled space where many others have failed. It also highlights the potential of using AI and genetics to reduce adverse drug reactions and restore public trust in the pharmaceutical industry. Additionally, it mentions the FDA's decision to remove risk evaluation and mitigation strategies for certain cell and gene therapies, as well as recent developments in ultrarare therapies, cancer treatments, and regulatory changes. The text provides information on the HHS overhaul by the numbers, including rehiring hundreds of employees but still operating with reduced staff.…

1 Pharma and Biotech Daily: Keeping You Informed on the Latest Advancements 2:08
2:08
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب2:08
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.## Breakthrough in Cancer TreatmentExciting news in the world of oncology as a new breakthrough in cancer treatment has been announced. Researchers have discovered a novel therapy that targets specific mutations in cancer cells, leading to significantly improved outcomes for patients. This groundbreaking treatment is set to revolutionize the way we approach cancer care and could potentially save countless lives in the future.## FDA Approval for New DrugIn other news, the FDA has granted approval for a new drug that shows promising results in the treatment of a rare genetic disorder. This drug has undergone rigorous testing and has been shown to be both safe and effective in clinical trials. The approval of this medication represents a major milestone in the field of rare disease treatment and offers hope to patients who previously had limited options for managing their condition.## Collaboration between Pharmaceutical CompaniesA collaboration between two leading pharmaceutical companies has been announced, with the goal of developing innovative therapies for a range of diseases. This partnership brings together the unique expertise and resources of both companies, potentially leading to the discovery of new treatments that could benefit patients worldwide. This collaboration highlights the importance of working together to address unmet medical needs and advance the field of medicine.## Advancements in Gene TherapyExciting advancements have been made in the field of gene therapy, with researchers reporting promising results in early clinical trials. Gene therapy has the potential to treat a wide range of genetic disorders by replacing or modifying faulty genes. These latest developments represent a significant step forward in the field of genetic medicine and offer hope to patients who previously had limited treatment options.## ConclusionIn conclusion, these recent developments in the world of Pharma and Biotech are not only groundbreaking but also offer hope for patients facing serious medical conditions. From breakthroughs in cancer treatment to advancements in gene therapy, the future of medicine is looking brighter than ever. Stay tuned for more updates on these exciting developments as we continue to follow the latest news in Pharma and Biotech.…

1 Pharma and Biotech Daily: RSV Vaccine Expansion, Biogen's Deal Struggle, and More! 0:51
0:51
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب0:51
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Health Secretary Robert F. Kennedy Jr. endorsed the expanded use of RSV vaccines for people aged 50-59 who are at risk of severe disease, following recommendations from ACIP members he had previously fired. Biogen CEO Chris Viehbacher tried to strike a deal with Sage as the company searched for a way forward after setbacks, but Sage was not interested. In other news, late-stage stumble for Cosentyx sets Novartis back in autoimmune conditions, and Gilead eyes HIV market domination with a twice-yearly treatment. Additional stories include biotech leaders and investors urging the FDA to maintain access to Mifepristone, Regeneron scoring a nod for a bispecific drug for multiple myeloma, and the increasing demand for bioinformatics roles in the industry.…

1 Pharma and Biotech Daily: M&A Surge and Regulatory Updates in the Industry 1:29
1:29
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب1:29
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. A judge has suspended mass layoffs at the Department of Health and Human Services, ruling that the staff cuts are likely unlawful as the agency does not have the authority to make such changes without Congress. In other news, private equity firms have recently acquired Bluebird Bio, a gene therapy biotech company, raising questions about their motivations. Additionally, RFK Jr. is advocating for changes to the vaccine injury compensation program to include COVID-19 vaccines, while the FDA is considering regulatory action on Argenx's Vyvgart Hytrulo due to safety concerns. The article also discusses Gilead's plans for dominance in the HIV market with a new drug, and other updates in the pharmaceutical industry.Private equity firms are increasingly targeting biotech companies, with Bluebird Bio recently being acquired by two firms. The first half of the year saw a surge in M&A activity in the pharmaceutical industry, with big pharmas like Eli Lilly and Novartis making multiple deals. Deals related to Alzheimer's disease also saw a significant increase following the approval of new treatments. Gilead is expanding its presence in the HIV market with a new drug, while GSK is also vying for market dominance. Other notable deals include AbbVie's acquisition of Capstan and Novartis' partnership for cardiovascular disease targets. Overall, the industry is seeing increased activity and interest from private equity firms and big pharma companies.…

1 The Pharma and Biotech Daily: Beckley's Nasal Spray Success, M&A Activity Surge, and Job Opportunities 1:14
1:14
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب1:14
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Beckley's psychedelic nasal spray, BPL-003, has successfully cleared Phase II trials for treatment-resistant depression, showing robust efficacy data. Analysts predict the asset could reach peak market sales of $1 billion. This paves the way for late-stage development and a proposed merger with atai life sciences. In other news, M&A activity saw a significant increase in June, with big pharmas like Eli Lilly, Sanofi, and Novartis making multiple deals. The FDA's decision to remove risk evaluation and mitigation strategies from approved CAR T cancer therapies has been well-received by the cell and gene therapy community. Additionally, Argenx has made a $1.5 billion acquisition of Unum Therapeutics' macrocyclic peptides, aimed at "undruggable" targets. Moderna, Merck, UroGen, and other companies received regulatory nods for various treatments in June. Evotec is hosting a webinar on preserving quality in the pharma industry amidst financial challenges on July 16. Job opportunities in the industry include positions at Biomarin Pharmaceutical Inc., Regeneron Pharmaceuticals, and AbbVie.…

1 Pharma and Biotech Daily: AbbVie's Acquisition, Moderna's Flu Vaccine, and More! 1:04
1:04
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب1:04
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.AbbVie's acquisition of Capstan Therapeutics for $2.1 billion highlights the increasing trend of mergers and acquisitions in the biopharmaceutical industry. This move gives AbbVie access to Capstan's novel in vivo CAR T therapy for autoimmune diseases. Meanwhile, Moderna's mRNA flu vaccine has shown promising results, outperforming the current standard shot in adults aged 50 and older. The FDA's deployment of an AI tool has sparked concerns regarding its readiness and legal implications.Following the approval of monoclonal antibodies for Alzheimer's disease, there has been a surge in deals related to research in this area. Wacker Biotech is now offering comprehensive biologics manufacturing services, covering everything from concept to commercialization.Additional updates cover various topics such as clinical trials progress, industry layoffs, and discussions on vaccine safety. Job opportunities within the biopharmaceutical sector are also available for those interested.…

1 Pharma and Biotech Daily: Supreme Court Ruling, Depression Drug Updates, and FDA Decisions 1:02
1:02
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب1:02
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.The Supreme Court ruled in favor of Gilead in an HIV prevention case, leaving decisions on coverage of the pre-exposure prophylaxis drug to a task force led by RFK Jr. A depression drug missed its phase II endpoint but showed positive signals in other areas. The ACIP committee is scrutinizing the safety of mRNA vaccines, while analysts are focusing on safety data presented by Novo, Lilly, and Amgen at the American Diabetes Association meeting.In other news, the FDA blocked an accelerated path for a Becker muscular dystrophy drug, Altimmune's stock dropped due to mixed mid-stage data, and Calico entered into an aging research deal with Mabwell. ACIP also voted to remove thimerosal from all flu vaccines, and former regulators expressed concerns about the integrity of the FDA approval process. These updates cover a range of developments in the pharmaceutical industry, shedding light on key advancements and challenges within the healthcare sector.…

1 Pharma and Biotech Daily: Navigating the Latest News in the Industry 0:54
0:54
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب0:54
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Former FDA official Peter Marks criticized the agency's new risk-based COVID-19 vaccine framework, stating it contradicts the administration's transparency and science standards. The CDC's advisory committee recommended Merck's infant RSV vaccine, and Novavax's approval delay raised concerns about politicization of drug approval processes. Lilly's Verve deal revealed regulatory turmoil following Marks' resignation. Meanwhile, Trump's CDC pick supports vaccine safety, Novartis made a large bet on cardiovascular disease targets, and RFK cut US funding from vaccine alliance Gavi. The biopharma industry is hiring less international talent, and pharma companies face challenges with failed immuno-oncology projects. Evotec is hosting a webinar on preserving quality in the pharmaceutical industry.…
P
Pharma and BioTech Daily

1 Pharma and Biotech Daily: Your Essential Dose of Industry News 2:07
2:07
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب2:07
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.The CDC's new vaccine advisors are meeting with an unexpected agenda today, including discussions on topics such as Sanofi and Gilead's protein degrader deals, the FDA's review of Sarepta's gene therapy, and a contentious hearing with RFK Jr. over vaccines. The meeting marks the beginning of a new era for the influential vaccine committee. The FDA has named a psychedelic proponent as CDER deputy director, while Nektar has declared a Phase IIb win for eczema treatment. Experts say conflicts of interest among axed ACIP members are a "red herring," and the pharma industry is facing turmoil in failed immuno-oncology projects. Prescription drug sales are projected to hit $1.75 trillion by 2030, thanks to GLP-1s. Transitioning to the next news, a major pharmaceutical company has announced a breakthrough in cancer research, potentially changing the landscape of treatment options for patients worldwide. This development comes at a time when the industry is seeing significant advancements in personalized medicine and targeted therapies. Moving on to regulatory updates, the FDA has recently approved a new drug for a rare disease, providing hope for patients who previously had limited treatment options. This decision showcases the agency's commitment to expediting the approval process for innovative therapies that address unmet medical needs. In other news, a biotech startup has secured funding for its groundbreaking technology that aims to revolutionize drug delivery methods. This investment highlights the growing interest in novel approaches to drug development and underscores the importance of innovation in the industry.Wrapping up today's episode, we take a look at the latest trends in digital health, with companies leveraging artificial intelligence and big data analytics to improve patient outcomes and streamline healthcare delivery. These technological advancements have the potential to transform the way healthcare is delivered and pave the way for a more efficient and patient-centric system. That's all for today's episode of Pharma and Biotech daily. Stay tuned for more updates on the latest developments in the pharmaceutical and biotechnology sectors.…
P
Pharma and BioTech Daily

1 Pharma & Biotech Daily: FDA Leadership Turnover and Industry Challenges 0:59
0:59
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب0:59
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. The FDA's Center for Drug Evaluation and Research (CDER) head, Jacqueline Corrigan-Curay, is leaving the agency in July, becoming the latest in a series of FDA leaders to depart. Eli Lilly is facing concerns about gastrointestinal side effects for their weight loss pill, Orfoglipron, despite brushing off these worries. Vertex's cell therapy for diabetes shows promise, but questions remain about its market potential. HHS Secretary Robert F. Kennedy Jr. has restacked the CDC's vaccine advisory committee, claiming conflicts of interest within the previous group, which experts argue may impact the committee's apolitical nature. Prothena has downsized following a failure in an Al amyloidosis trial, and Novavax is adapting to regulatory uncertainty. Overall, the FDA is experiencing significant turnover in leadership, and challenges persist in drug development and regulation.…
P
Pharma and BioTech Daily

1 Navigating Regulatory Uncertainty: Updates from the Pharma and Biotech World 1:10
1:10
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب1:10
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Nicole Verdun has exited the FDA as CBER director, allowing Vinay Prasad to consolidate power within the agency. Prasad is seen as a stabilizing and trustworthy figure within the rapidly changing FDA, especially since the departure of Peter Marks in late March. Novavax is adapting to regulatory uncertainty following the delayed approval of its next-generation COVID-19 vaccine. The company is relying on agility and a diverse pipeline to navigate changing regulations. Additionally, the FDA has frozen trials shipping cells to countries like China due to new export control policies. Exemptions have allowed companies to ship biological materials overseas, but this practice is now being restricted. Zealand's GLP-1/GLP-2 drug has shown promising results in weight loss trials, with analysts believing there is potential for further improvement. Intellia Therapeutics aims to transform the lives of people with severe diseases through genome editing treatments. Overall, the biotech industry is facing various challenges and changes, requiring companies to stay adaptable and innovative.…
P
Pharma and BioTech Daily

1 Breaking News in Pharma and Biotech: Gilead's Yeztugo Approval, Biopharma Deal Premiums, BioNTech-CureVac Merger, and AI in Precision Oncology 0:46
0:46
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب0:46
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Gilead has received approval for a twice-yearly HIV drug, Lenacapavir, which will be marketed as Yeztugo, potentially redefining the prep market. In other news, biopharma deal premiums show intense negotiations, with Sanofi paying a high premium for Vigil Neuroscience and Novartis acquiring Regulus for $800 million upfront. BioNTech is merging with CureVac after previously criticizing its failed COVID vaccine program. AI is becoming crucial in precision oncology, with companies like AstraZeneca and Pfizer using computational power to design trials and understand challenging cancers better. Intellia Therapeutics aims to transform lives with genome editing treatments.…
P
Pharma and BioTech Daily

1 Biotech Buzz: Financial Challenges, Mergers, and Strategic Shifts in the Pharma World 1:51
1:51
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب1:51
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Ey's 2025 Biotech Beyond Borders report reveals that over one-third of biotech companies have less than a year of cash left, indicating financial challenges within the industry. The report emphasizes the need for a return to basics for biotech companies. Additionally, industry experts are discussing FDA Commissioner Makary's push to modernize the FDA and speed up regulatory processes. Scholar Rock has seen positive results with a weight loss combination therapy, and the FDA's new voucher program has been met with some optimism from biotech investors. Overall, the biotech industry is facing financial struggles, but there are opportunities for growth and innovation in the future.BioNTech and CureVac were once enemies, with BioNTech attacking CureVac's "failed" COVID vaccine program. However, they are now merging, with BioNTech buying CureVac in a $1.25 billion all-stock acquisition. The biopharma industry has seen a string of dramatic deals, with companies paying high premiums for acquisitions. This includes Sanofi paying a 300% premium for Vigil Neuroscience and Novartis acquiring Regulus for $800 million upfront. Overseas biosimilars companies can be sued in the US, potentially dissuading them from targeting the US market and benefiting domestic producers. Lilly's $1.3 billion acquisition of Verve in the gene editing space has been met with skepticism from analysts. Biotechs are seeking partnerships as the industry moves forward, with events like BIO2025 kicking off. The industry is facing challenges such as layoffs at companies like Lycia, while AstraZeneca makes a $5.3 billion AI bet with China's CSPC for chronic disease pills. Overall, the biopharma industry is experiencing a period of intense deal-making and strategic shifts.…
P
Pharma and BioTech Daily

1 Pharma and Biotech Daily: Stay Informed on Industry Trends and M&A Activity! 0:46
0:46
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب0:46
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Eli Lilly's acquisition of Verve Therapeutics for $1.3 billion has sparked interest in the gene editing space, with analysts speculating on potential market boosts. Recent M&A activity in the biopharma sector has accelerated, despite challenges from drug pricing policies and tariff threats. In other news, a court order has restored canceled NIH grants, and a CDC scientist has resigned over vaccine regulation concerns. Updates on various biotech developments, including Intellia Therapeutics' aim to develop genome editing treatments for severe diseases, are also making headlines.Stay tuned for more updates on the latest developments in the pharmaceutical industry.…
P
Pharma and BioTech Daily

1 Pharma and Biotech Daily: Sarepta's Setback, Sage's Success, and Promising Developments Ahead 0:48
0:48
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب0:48
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Sarepta Therapeutics faced a drop in shares due to a second death from acute liver failure in a patient receiving their DMD gene therapy. On the other hand, Sage Therapeutics had a positive outcome with a $795 million acquisition by Supernus, surpassing a bid from Biogen. Meanwhile, Lilly saw promising results in a phase I study of their amylin/tirzepatide combo for weight loss. J&J's dual-targeting CAR T-cell therapy showed an 80% complete response rate in early lymphoma studies, demonstrating potential in the field. In addition, Intellia Therapeutics is dedicated to developing potentially curative genome editing treatments for severe diseases, showing promise for future advancements in healthcare.…
P
Pharma and BioTech Daily

1 Vaccine Skeptics, AI Bets, and Industry Challenges: The Pharma and Biotech Daily Update 0:58
0:58
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب0:58
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Two new members of Kennedy's revamped CDC vaccine advisory committee, Martin Kulldorff and Robert Malone, have a history of being paid expert witnesses in vaccine cases against Merck. They are known for being vaccine skeptics and have questioned the use of mRNA technology in vaccines. Meanwhile, Moderna has received an expanded label for its mRNA RSV shot, but there are concerns about the new ACIP members' questioning of mRNA technology.In other news, Astrazeneca has made a $5.3 billion bet on AI with China's CSPC for chronic disease pills. ADC Therapeutics is cutting staff and closing a research facility, while Biontech has acquired vaccine rival Curevac. The AMA has called for a Senate probe into RFK Jr. after the removal of CDC vaccine advisors.Overall, the industry is facing challenges with layoffs and a tight job market.…
P
Pharma and BioTech Daily

1 The Latest in Pharma and Biotech: CDC Shake-Ups, Vaccine Controversies, and New Approvals 1:21
1:21
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب1:21
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.The CDC has reinstated around 460 employees who were previously fired, with the rehired staff working on viral disease prevention efforts and sexual health testing labs. This comes amid protests and shake-ups at the agency, including the overhaul of the vaccine advisory committee. Experts are concerned about newly appointed members, some of whom are known anti-vaxxers, potentially relitigating recommendations. Sen. Bill Cassidy is being urged to step up in response to these concerns.In other news, NuVation has received FDA approval for its oral lung cancer drug, Biontech has acquired CureVac in a $1.25 billion all-stock deal, and RFK Jr. has named new CDC vaccine advisors following a "clean sweep." Additionally, InVitro Cell Research is focused on discovering interventions to slow aging and prevent age-related diseases and is hiring scientists. The newsletter also includes information on layoffs at Genentech and Vertex.RFK Jr. has named eight new members to the CDC vaccine committee, replacing the 17 members he removed earlier in the week. The new choices seem to align with Kennedy's anti-vaccine views, causing concern among analysts. The HHS secretary's decision to appoint these scientists has raised questions about the committee's future direction.…
P
Pharma and BioTech Daily

1 Pharma and Biotech Daily: Your Essential Morning Update on the Industry 1:56
1:56
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب1:56
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The American Medical Association is calling for a Senate probe into RFK Jr. after he removed all 17 members of the CDC's vaccine advisory board. They are also urging an immediate reversal of the HHS Secretary's decision. In other news, FDA leaders promise support for gene therapy as it faces challenges, Novo Nordisk invests over $800 million in discovering oral obesity drugs, and a new company, InVitro Cell Research, focuses on interventions to slow aging and prevent age-related diseases. FDA Commissioner Marty Makary and CBER Director Vinay Prasad published an article outlining the FDA's priorities, including accelerating cures and deploying artificial intelligence quickly. Other news includes Lilly's muscle-preserving treatment pact, Vertex laying off staff after axing a diabetes asset, and Genentech reshuffling in South San Francisco. Recursion cuts workforce by 20%.FDA leaders have pledged support to gene therapy makers as the industry faces challenges in commercialization. Despite huge valuations, gene therapies are struggling to reach the market. Poor communication about the value of groundbreaking treatments is hindering their prospects. Right of first negotiation deals do not always lead to mergers and acquisitions, as found by Jefferies in their analysis of licensing deals. Trilink's new comprehensive IVT kit simplifies the production of mRNAs. In other news, Lilly strikes a $650 million deal for a muscle-preserving treatment, Odyssey ends its quest for Nasdaq, BMS expands its radiopharma presence, and SpliceBio secures $135 million in funding for protein splicing medicines. Novo ups its obesity efforts with an $800 million pact, while Cullinan makes a $700 million deal for autoimmune T cell engager in China.Thank you for listening to Pharma and Biotech Daily.…
P
Pharma and BioTech Daily

1 Pharma and Biotech Daily: Stay Informed on the Latest Industry Updates 1:05
1:05
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب1:05
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Robert F. Kennedy Jr.'s removal of all members of the CDC's Advisory Committee on Immunization Practices has raised concerns about the upcoming meeting later this month. Analysts fear that the committee may become more sympathetic to anti-vaccine viewpoints. In other news, Merck has received FDA approval for an RSV antibody, Gilead has paused five HIV trials but Lenacapavir remains safe, and the FDA has reinstated a previously disbanded generic drug policy panel. Gilead has expressed faith in its HIV combo therapy and pledged to work with regulators to resolve the hold on its trials. In vitro cell research is focused on discovering interventions to slow aging and prevent age-related diseases.Kennedy's vaccine campaign is seen as breeding more distrust, while Metsera's weight loss injection has shown positive results. Merck is moving forward with an oral PCSK9 inhibitor. Thank you for tuning in to Pharma and Biotech daily for the latest updates in the pharmaceutical and biotechnology industries.…
P
Pharma and BioTech Daily

1 Pharma and Biotech Daily: Weight Loss Breakthroughs, Vaccine Advisor Shakeups, and RNA Therapeutics Expansion 1:24
1:24
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب1:24
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Metsera's new long-acting amylin injection, met-233i, has shown promising weight loss results over eight months, leading to a rise in shares. Meanwhile, CDC vaccine advisors are either being pushed out or leaving their positions. Other top stories include Sirna's expansion beyond the liver, Keros returning $375 million to investors, and ACIP members receiving termination notices. In vitro cell research is focused on slowing aging and preventing age-related diseases. Updates on Merck's oral PCSK9 inhibitor, Sanofi and Regeneron's Dupixent effectiveness, and Avidity's muscular dystrophy drug are also highlighted.The expansion of RNA therapeutics is discussed, with multiple companies aiming to target small interfering RNA to various organs by 2030. Uniqure's regulatory progress in developing a gene therapy for Huntington's disease has sparked optimism, although past disappointments for patients are noted. Perspective Therapeutics presents new data on neuroendocrine tumor treatment at ASCO25. Concerns about RFK Jr.'s vaccine campaign and its potential to increase distrust in vaccines are raised in the editorial. Cancer news, cell and gene therapy updates, upcoming events, job listings, and a call for reader suggestions on coverage topics are also covered.…
P
Pharma and BioTech Daily

1 Pharma and Biotech Daily: Your Essential Update on the Latest Developments 2:40
2:40
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب2:40
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##News 1: FDA approves new drug for treatment of rare genetic diseaseIn a significant development for the rare disease community, the FDA has approved a new drug for the treatment of a rare genetic disease. The drug, which is the first of its kind, has shown promising results in clinical trials and is expected to provide much-needed relief for patients suffering from this condition.##News 2: Biotech company announces breakthrough in cancer researchA leading biotech company has announced a major breakthrough in cancer research. The company's new treatment has shown significant efficacy in treating a variety of cancers, offering hope to patients who previously had limited treatment options. This development marks a significant step forward in the fight against cancer.##News 3: Pharma company reports positive results in COVID-19 vaccine trialsA pharmaceutical company has reported positive results in clinical trials for its COVID-19 vaccine candidate. The vaccine has shown high efficacy rates in preventing infection and reducing the severity of symptoms in vaccinated individuals. This news comes as a welcome development in the ongoing battle against the global pandemic.##News 4: Biotech startup secures funding for innovative gene therapyA promising biotech startup has secured funding for its innovative gene therapy approach. The therapy, which targets a range of genetic disorders, has shown promising results in preclinical studies and is now moving towards clinical trials. This funding will help accelerate the development of the therapy and bring it one step closer to market availability.##News 5: Pharma giant announces collaboration with leading research institutionA major pharmaceutical company has announced a collaboration with a leading research institution to advance drug discovery efforts. The partnership aims to leverage the expertise of both organizations to accelerate the development of new treatments for a variety of diseases. This collaboration represents a significant step forward in the quest for innovative therapies.##News 6: Biotech conference showcases latest advancements in gene editing technologyA recent biotech conference showcased the latest advancements in gene editing technology. Researchers presented cutting-edge techniques that have the potential to revolutionize the field of genetic engineering. These advancements hold promise for developing new treatments for a wide range of diseases and disorders.##That's all for today's episode of Pharma and Biotech Daily. Stay tuned for more updates on the latest developments in the world of pharmaceuticals and biotechnology. Thank you for listening!…
P
Pharma and BioTech Daily

1 Pharma and Biotech Daily: Lawsuits, Regulatory Progress, and Market Moves 0:57
0:57
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب0:57
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Fired employees from the Department of Health and Human Services are suing Robert F. Kennedy Jr. and Elon Musk, claiming their terminations were based on inaccurate and error-ridden information. The lawsuit alleges that HHS leadership knew the records used to guide layoff decisions were flawed. UniQure's regulatory progress has sparked optimism for Huntington's disease patients, with analysts reacting positively to the company's accelerated approval pathway for a gene therapy submission in 2026. Cullinan has made a back-heavy deal in China worth over $700 million for autoimmune T cell engager technology, while Sarepta has won FDA's platform technology designation for gene therapy development. Rapt is shrinking after discontinuing a drug, agileAD is gearing up to challenge J&J in the multiple myeloma Car-T market, and Lilly has signed a deal for long-acting obesity drugs.…
P
Pharma and BioTech Daily

1 Biotech Buzz: The Latest in Pharma and Biotech News 2:00
2:00
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب2:00
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world.Jefferies predicts an increase in small tuck-in deals in the biotech industry as companies face challenges accessing capital. Companies and industry groups are offering solutions to mitigate the impact of Trump tariffs on rare disease, cell, and gene therapy. Pitchbook suggests a shift towards more sustainable investing in biotech VC firms. Gilead is gearing up to challenge J&J in the $20 billion multiple myeloma CAR-T market. PTP's generative AI is revolutionizing data summaries for biotech QC workflows. Sanofi recently acquired Blueprint for $9.5 billion, while BMS has committed up to $11 billion with Biontech. Lilly has signed a deal worth up to $870 million, and Regeneron is investing nearly $2 billion in a Chinese obesity drug. Merck's CEO is emphasizing diversity in operations following the defeat of an anti-DEI measure. Immuno-oncology drugs Keytruda and Opdivo may face scrutiny in the near future.In other news, Vigil Neuroscience's Trem2 antibody for a rare brain disease failed in a Phase II trial shortly after Sanofi's acquisition of the company. Analysts believe the results were not surprising and should not impact the deal. Lilly has signed a deal worth up to $870 million to develop a long-acting GLP-1 obesity drug, while the FDA is committed to making rare disease drugs available at the first sign of promise. Pharma tuck-in deals are increasing after a slow first quarter for small biotechs. BioAgc Biologics will be attending Bio International in Boston to discuss their global drug production capabilities.Stay tuned for more updates on investing in research, welcoming global talent, the biotech VC cycle, Gilead's challenge to J&J in the multiple myeloma CAR-T market, and much more. Upcoming events and job listings in the pharmaceutical industry are also featured in our newsletter.Thank you for tuning in to Pharma and Biotech daily.…
مرحبًا بك في مشغل أف ام!
يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.